2018
DOI: 10.1016/j.bjid.2018.02.002
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: No significant increase of basal T-cell proliferation among Human T cell Leukemia Virus type 1 co-infected was observed. This interaction may be implicated in liver damage, worsening the prognosis of co-infected patients or, on the contrary, inducing a higher spontaneous clearance of Hepatitis C Virus infection in Human T cell Leukemia Virus type 1 co-infected patients.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
3
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
3
1

Relationship

2
2

Authors

Journals

citations
Cited by 4 publications
(3 citation statements)
references
References 34 publications
0
3
0
Order By: Relevance
“…The incidence of ATLL and HAM/TSP varies from 0.5% to 10% among HTLV-1 infected subjects, increasing morbidity and mortality rates [9] Additionally, treatment of coinfections, such as HIV and HCV, can be delayed due to HTLV-1 promoting an inefficacious increase in CD4+ cells, leading to a delay in antiretroviral therapy (ART) initiation and, possibly, inefficacious HCV clearance [10][11][12][13]. In endemic countries, parasitic coinfection with Strongyloides stercoralis also increases morbidity and mortality [12].…”
Section: Introductionmentioning
confidence: 99%
“…The incidence of ATLL and HAM/TSP varies from 0.5% to 10% among HTLV-1 infected subjects, increasing morbidity and mortality rates [9] Additionally, treatment of coinfections, such as HIV and HCV, can be delayed due to HTLV-1 promoting an inefficacious increase in CD4+ cells, leading to a delay in antiretroviral therapy (ART) initiation and, possibly, inefficacious HCV clearance [10][11][12][13]. In endemic countries, parasitic coinfection with Strongyloides stercoralis also increases morbidity and mortality [12].…”
Section: Introductionmentioning
confidence: 99%
“…The incidence of ATLL and HAM/TSP varies from 0.5% to 10% among HTLV-1 infected subjects, increasing morbidity and mortality rates [10][11][12][13]. Also, treatment of co-infections, such as HIV and HCV, can be delayed due to HTLV-1 promoting an inefficacious increase in TCD4+ cells, leading to a delay in antiretroviral therapy (ART) initiation and, possibly, inefficacious HCV clearance [14][15][16][17]. In endemic countries, parasitic co-infection with Strongyloides stercoralis also increases morbidity and mortality [16].…”
Section: Introductionmentioning
confidence: 99%
“…More studies claim that CD4+ count increases in co-infected individuals [18,27,29,31,36,39,41]. Nevertheless, some research reported similar CD4+ counts in co-infected and mono-infected patients [21,22,29,43]. One study reported an elevated initial CD4+ count in co-infected patients while observing a decreased CD4 : CD8 ratio in the last test [28].…”
mentioning
confidence: 99%